Pregled bibliografske jedinice broj: 1253901
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey // Cancers, 14 (2022), 22; 5530-5530 doi:10.3390/cancers14225530. (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1253901 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Simultaneous Onset of Haematological Malignancy and
COVID: An Epicovideha Survey
Autori
Cattaneo C, Salmanton-García J, Marchesi F, El- Ashwah S, Itri F, Weinbergerová B, Gomes Da Silva M, Dargenio M, Dávila-Valls J, Martín-Pérez S, Farina F, Van Doesum J, Valković T, Besson C, Poulsen CB, López-García A, Žák P, Schönlein M, Piukovics K, Jaksic O, Cabirta A, Ali N, Sili U, Fracchiolla N, Dragonetti G, Adžić-Vukičević T, Marchetti M, Machado M, Glenthøj A, Finizio O, Demirkan F, Blennow O, Tisi MC, Omrani AS, Navrátil M, Ráčil Z, Novák J, Magliano G, Jiménez M, Garcia-Vidal C, Erben N, Del Principe MI, Buquicchio C, Bergantim R, Batinić J, Al-Khabori M, Verga L, Szotkowski T, Samarkos M, Ormazabal- Vélez I, Meers S, Maertens J, Pinczés LI, Hoenigl M, Drgoňa Ľ, Cuccaro A, Bilgin YM, Aujayeb A, Rahimli L, Gräfe S, Sciumè M, Mladenović M, Çolak GM, Sacchi MV, Nordlander A, Berg Venemyr C, Hanáková M, García-Poutón N, Emarah Z, Zambrotta GPM, Nunes Rodrigues R, Cordoba R, Méndez GA, Biernat MM, Cornely OA, Pagano L.
Izvornik
Cancers (2072-6694) 14
(2022), 22;
5530-5530
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
COVID-19 ; haematological malignancy onset ; outcome ; prognostic factors ; treatment.
Sažetak
Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%) ; 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < ; 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count > ; 500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.
Izvorni jezik
Engleski
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus